Lunesta Clears FDA; Sepracor Plans 2005 Release Of Depression Data
Executive Summary
Sepracor plans to present data from its completed Lunesta (eszopiclone) Phase IIIb/IV trial for the treatment of insomnia in patients suffering from depression in 2005
You may also be interested in...
Ambien CR Approval Includes Sleep Maintenance, Long-Term Use
The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents
Ambien CR Approval Includes Sleep Maintenance, Long-Term Use
The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents
Takeda To Highlight Rozerem Melatonin Receptor Mechanism Of Action
Takeda's Rozerem promotions will highlight ramelteon's melatonin receptor activity and lack of abuse potential following FDA approval of the insomnia therapy